Physicochemical characterization and dissolution properties of meloxicam-gelucire 50/13 binary systems

Scientia Pharmaceutica

Volumn 79, Issue 2, 2011, Pages 375-386

  El Badry, Mahmoud ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Assiut University   (Egypt)

Author keywords

Anti inflammatory activity; Dissolution; Meloxicam; Powder X ray diffractometry analysis; Scanning electron microscopy; Solid dispersion; Spray drying

Indexed keywords

GELUCIRE; MELOXICAM;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG SOLUBILITY; MELTING POINT; NONHUMAN; PAW EDEMA; PH; PHYSICAL CHEMISTRY; RAT; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; X RAY DIFFRACTION;

EID: 79959305480     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1101-22     Document Type: Article

References (24)

1. Luger P, Daneck K, Engel W, Trummlitz G, Wagnar K. Structure and physicochemical properties of meloxicam, a new NSAID. Eur J Pharm Sci. 1996; 4: 175-187. doi:10.1016/0928-0987(95)00046-1.
2. Hanft G, Turck D, Scheuerer S, Sigmund R. Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations. Inflamm Res. 2001; 50: 35-37. doi:10.1007/PL00000219.
3. Martinez M, Viota-Gallardo J, Benavides M, Lopez-Duran J, Visitacion L. Rheological behavior of gels and meloxicam release. Int J Pharm. 2007; 333: 17-23. doi:10.1016/j.ijpharm.2006.09.045.
4. Gupta S K, Bansal P, Bhadwaj R K, Jaiswal J, Velpandian T. Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gel in animal models: pharmacokinetic parameters after topical application. Skin Pharmacol Appl Skin Physiol. 2002; 15: 105-111. doi:10.1159/000049397.
5. Yazdanian M, Briggs K, Jankovsky C, Hawi A. The "high solubility" definition of the current FDA guidance on biopharmaceutical classification System may be too strict for acidic drugs. Pharm Res. 2004; 21: 293-299. doi:10.1023/B:PHAM.0000016242.48642.71.
6. Ainaoui A, Ouriemchi EM, Badah D, EL-Amrani MK, Verganud JM. Process of drug release with oral dosage forms with lipidic gelucire matrix. J Polymer Eng. 1997; 17: 245-257.
7. Craig DQM. The physical characterization of Gelucire 50/13. In: Gattefosse (Ed). Bulletin Technique Gattefosse, No.89, Saint Priest, Cedex, France, 1996 pp. 39-50.
8. Leuner C, Dressmen J. Improving drug solubility for oral delivery using solid dispersion. Eur J Pharm Biopharm. 2000; 50: 47-60. doi:10.1016/S0939-6411(00)00076-X
9. EL-Badry M, Fetih G, Fathy M. Study of Solid Dispersions of Indomethacin in Gelucire 50/13 and PEG4000. Saudi Pharm J. 2009; 17: 217-225. doi:10.1016/j.jsps.2009.08.006.
10. Yassin AB, Alanazi FK, El-Badry M, Alsarra IA, Barakat NS. Preparation and Characterization of Spironolactone-Loaded Gelucire Microparticles Using Spray- Drying Technique. Drug Dev Ind Pharm. 2009; 35: 297-304. doi:10.1080/03639040802302157.
11. Muller CR, Bassani VL, Pohlman AR, Michalowski CB, Petrovick PR, Guterres SS. Preparation and characterization of spray-dried polymeric nanocapsiles. Drug Dev Ind Pharm. 2000; 26: 343-347. doi:10.1081/DDC-100100363.
12. Moretti M D, Gavini E, Juliano C, Pirisino G, Giunchedi P. Spray-dried microspheres containing ketoprofen formulated into capsules and tablets. J Microencapsul. 2001; 18: 111-121. doi:10.1080/026520401750038647.
13. Asada M, Takahashi H, Okamoto H, Tanino H, Danjo K. Theophylline particle design using chitosan by the spray drying. Int J Pharm. 2004; 270: 167-174. doi:10.1016/j.ijpharm.2003.11.001.
14. Dollo G, Le Corre P, Guerin A, Chevanne F, Burgot J L, Levege R. Spray-dried redispersible oil-in-water emulsion to improveoral bioavailability of poorly soluble drugs. Eur J Pharm Sci. 2003; 19: 273-280. doi:10.1016/S0928-0987(03)00134-9.
15. Eldem T, Speiser P, Hincal A. Optimization of spray dried and congealed lipid micropellet and characterization of their surface morphology by scanning electron microscopy. Pharm Res. 1991; 8: 47-54. doi:10.1023/A:1015874121860.
16. EL-Badry M, Fathy M. Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersion in polyvinylpyrrolidone K-30. Drug Dev Ind Pharm. 2006; 32: 141-150. doi:10.1080/03639040500465983.
17. Vippagunta SR, Maul KA, Tallavajhala S, Grant DJW. Solid state characterization of nifedipine solid dispersions. Int J Pharm. 2002; 236: 111-123. doi:10.1016/S0378-5173(02)00019-4.
18. Aghivesh RS, Bhalchandra U, Chhanda JK. Design, Optimization, Preparation and evaluation of dispersion granules of valsartan and formulation into tablets. Curr Drug Deliv. 2009; 6: 28-37. doi:10.2174/156720109787048258.
19. Ahuja N, Katare OP, Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of poorly watersoluble drug using water soluble carriers. Eur J Pharm Biopharm. 2007; 65: 26-38. doi:10.1016/j.ejpb.2006.07.007.
20. Fini A, Moyano JR, Gines JM, Perez-Martinez JI, Rabasco AM. Diclofenac salts, II. Solid dispersion in PEG 6000 and Gelucire 50/13. Eur J Pharm Biopharm. 2005; 60: 99-111. doi:10.1016/j.ejpb.2004.11.005.
21. Passerini N, Perissutti B, Moneghini M, Voinvich D, Albertini B, Cavallari C, Rodriguez L. Characterization of carbamazepine gelucire 50/13 microparticles prepared by spray-congealing process using ultrasound. J Pharm Sci. 2002; 91: 699-707. doi:10.1002/jps.10085.
22. Chauhan B, Shimpi S, Paradkar A. Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersion with silicon dioxide by spray drying technique. Eur J Pharm Sci. 2005; 26: 219-230. doi:10.1016/j.ejps.2005.06.005.
23. Escribano E, Calpena A C, Queralt J, Obach R, Domenench J. Assessment of diclofenac permeation with different formulations: anti-inflammatory study of a selected formula. Eur J Pharm Sci. 2003; 19: 203-210. doi:10.1016/S0928-0987(03)00103-9.
24. Choel SC, Jun HW. Anti-inflammatory activity of ketoprofen gel on carrageenan induced edema in rats. J Pharm Sci. 1990; 79: 974-77. doi:10.1002/jps.2600791106.